KPRX 8-K: SEC filing

Kiora Pharmaceuticals

Filed with the SEC on Nov 12, 2026 · accession 0001372514-26-000093

KPRX filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Kiora Pharmaceuticals issued a press release announcing financial results for the quarter ended September 30, 2026, along with an update on clinical development progress.

For details, click here →How to read a 8-K →

Key details

RegistrantKiora Pharmaceuticals, Inc.

Chief financial officerMelissa Tosca

✦ Ask GOAX AI about this filing — what it means for KPRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KPRX?

Click here

Frequently asked questions

What did KPRX file with the SEC on Nov 12, 2026?

KPRX filed a 8-K (SEC filing). Kiora Pharmaceuticals issued a press release announcing financial results for the quarter ended September 30, 2026, along with an update on clinical development progress.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other KPRX SEC filings

Get alerts when KPRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

KPRX overview KPRX analysis KPRX news Latest SEC filings